Mayo Clinic has not designated the bond sale for a specific project, but the system noted it is planning large capital expenditures. Over the next five years, the system expects capital spending of $6.5 billion, according to the report.
“The specific uses of the net bond proceeds have not been determined, but debt financing is a routine element of Mayo Clinic’s capital formation,” a Mayo Clinic spokesperson told the Post Bulletin. “Debt financing is a routine element of Mayo Clinic’s long-term financial planning, and the current rate environment makes it an opportune time to issue bonds.”
The net benefit of the bond sale to Mayo Clinic will be $497.5 million after issuance costs are deducted, according to the report.
Read the full Post Bulletin article here.
More articles on healthcare finance:
Why rural hospital closures hit a record high in 2020
New York hospital takes $34M hit from nearly 2,700 canceled surgeries
Washington health system blames Cerner for bankruptcy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
